HUP0300332A2 - Bétablokkoló és koleszterinszint-csökkentő szert tartalmazó új gyógyszerkombináció és ezt tartalmazó gyógyszerkészítmények - Google Patents
Bétablokkoló és koleszterinszint-csökkentő szert tartalmazó új gyógyszerkombináció és ezt tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0300332A2 HUP0300332A2 HU0300332A HUP0300332A HUP0300332A2 HU P0300332 A2 HUP0300332 A2 HU P0300332A2 HU 0300332 A HU0300332 A HU 0300332A HU P0300332 A HUP0300332 A HU P0300332A HU P0300332 A2 HUP0300332 A2 HU P0300332A2
- Authority
- HU
- Hungary
- Prior art keywords
- solvate
- pharmaceutically acceptable
- acceptable salt
- salt
- betablocker
- Prior art date
Links
- 239000003529 anticholesteremic agent Substances 0.000 title 1
- 229940127226 anticholesterol agent Drugs 0.000 title 1
- 239000002876 beta blocker Substances 0.000 title 1
- 229940097320 beta blocking agent Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- -1 amosulolol Chemical compound 0.000 abstract 6
- 150000003839 salts Chemical class 0.000 abstract 4
- 239000012453 solvate Substances 0.000 abstract 4
- 239000002981 blocking agent Substances 0.000 abstract 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 abstract 2
- CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 abstract 1
- NXQMNKUGGYNLBY-GFCCVEGCSA-N (2r)-1-(3-methylphenoxy)-3-(propan-2-ylamino)propan-2-ol Chemical compound CC(C)NC[C@@H](O)COC1=CC=CC(C)=C1 NXQMNKUGGYNLBY-GFCCVEGCSA-N 0.000 abstract 1
- NXWGWUVGUSFQJC-GFCCVEGCSA-N (2r)-1-[(2-methyl-1h-indol-4-yl)oxy]-3-(propan-2-ylamino)propan-2-ol Chemical compound CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=C(C)N2 NXWGWUVGUSFQJC-GFCCVEGCSA-N 0.000 abstract 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 abstract 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 abstract 1
- UUOJIACWOAYWEZ-UHFFFAOYSA-N 1-(tert-butylamino)-3-[(2-methyl-1H-indol-4-yl)oxy]propan-2-yl benzoate Chemical compound C1=CC=C2NC(C)=CC2=C1OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1 UUOJIACWOAYWEZ-UHFFFAOYSA-N 0.000 abstract 1
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 abstract 1
- OZYYQTRHHXLTKX-UHFFFAOYSA-N 7-octenoic acid Chemical compound OC(=O)CCCCCC=C OZYYQTRHHXLTKX-UHFFFAOYSA-N 0.000 abstract 1
- JOATXPAWOHTVSZ-UHFFFAOYSA-N Celiprolol Chemical compound CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(C(C)=O)=C1 JOATXPAWOHTVSZ-UHFFFAOYSA-N 0.000 abstract 1
- YARKMNAWFIMDKV-UHFFFAOYSA-N Epanolol Chemical compound C=1C=CC=C(C#N)C=1OCC(O)CNCCNC(=O)CC1=CC=C(O)C=C1 YARKMNAWFIMDKV-UHFFFAOYSA-N 0.000 abstract 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- OMCPLEZZPVJJIS-UHFFFAOYSA-N Hypadil (TN) Chemical compound C1C(O[N+]([O-])=O)COC2=C1C=CC=C2OCC(O)CNC(C)C OMCPLEZZPVJJIS-UHFFFAOYSA-N 0.000 abstract 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 abstract 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 abstract 1
- YVPOVOVZCOOSBQ-AXHZAXLDSA-N [(1s,3r,7s,8s,8ar)-8-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2s)-2-methylbutanoate;pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1.C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 YVPOVOVZCOOSBQ-AXHZAXLDSA-N 0.000 abstract 1
- 229960002122 acebutolol Drugs 0.000 abstract 1
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 abstract 1
- 229960002213 alprenolol Drugs 0.000 abstract 1
- PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 abstract 1
- 229950010731 arotinolol Drugs 0.000 abstract 1
- BHIAIPWSVYSKJS-UHFFFAOYSA-N arotinolol Chemical compound S1C(SCC(O)CNC(C)(C)C)=NC(C=2SC(=CC=2)C(N)=O)=C1 BHIAIPWSVYSKJS-UHFFFAOYSA-N 0.000 abstract 1
- 229960002274 atenolol Drugs 0.000 abstract 1
- 229960004374 befunolol Drugs 0.000 abstract 1
- ZPQPDBIHYCBNIG-UHFFFAOYSA-N befunolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1OC(C(C)=O)=C2 ZPQPDBIHYCBNIG-UHFFFAOYSA-N 0.000 abstract 1
- 229960004324 betaxolol Drugs 0.000 abstract 1
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 abstract 1
- 229960003588 bevantolol Drugs 0.000 abstract 1
- HXLAFSUPPDYFEO-UHFFFAOYSA-N bevantolol Chemical compound C1=C(OC)C(OC)=CC=C1CCNCC(O)COC1=CC=CC(C)=C1 HXLAFSUPPDYFEO-UHFFFAOYSA-N 0.000 abstract 1
- 229960002781 bisoprolol Drugs 0.000 abstract 1
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 abstract 1
- 229960001035 bopindolol Drugs 0.000 abstract 1
- 229950002568 bucumolol Drugs 0.000 abstract 1
- CIJVBYRUFLGDHY-UHFFFAOYSA-N bucumolol Chemical compound O1C(=O)C=CC2=C1C(OCC(O)CNC(C)(C)C)=CC=C2C CIJVBYRUFLGDHY-UHFFFAOYSA-N 0.000 abstract 1
- 229950009385 bufetolol Drugs 0.000 abstract 1
- AKLNLVOZXMQGSI-UHFFFAOYSA-N bufetolol Chemical compound CC(C)(C)NCC(O)COC1=CC=CC=C1OCC1OCCC1 AKLNLVOZXMQGSI-UHFFFAOYSA-N 0.000 abstract 1
- VCVQSRCYSKKPBA-UHFFFAOYSA-N bunitrolol Chemical compound CC(C)(C)NCC(O)COC1=CC=CC=C1C#N VCVQSRCYSKKPBA-UHFFFAOYSA-N 0.000 abstract 1
- 229950008581 bunitrolol Drugs 0.000 abstract 1
- 229950009191 butofilolol Drugs 0.000 abstract 1
- NMBNQRJDEPOXCP-UHFFFAOYSA-N butofilolol Chemical compound CCCC(=O)C1=CC(F)=CC=C1OCC(O)CNC(C)(C)C NMBNQRJDEPOXCP-UHFFFAOYSA-N 0.000 abstract 1
- 229960004634 carazolol Drugs 0.000 abstract 1
- BQXQGZPYHWWCEB-UHFFFAOYSA-N carazolol Chemical compound N1C2=CC=CC=C2C2=C1C=CC=C2OCC(O)CNC(C)C BQXQGZPYHWWCEB-UHFFFAOYSA-N 0.000 abstract 1
- 229960001222 carteolol Drugs 0.000 abstract 1
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 abstract 1
- 229960004195 carvedilol Drugs 0.000 abstract 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 abstract 1
- 229960002320 celiprolol Drugs 0.000 abstract 1
- 229960005110 cerivastatin Drugs 0.000 abstract 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 abstract 1
- 229950003205 cetamolol Drugs 0.000 abstract 1
- UWCBNAVPISMFJZ-UHFFFAOYSA-N cetamolol Chemical compound CNC(=O)COC1=CC=CC=C1OCC(O)CNC(C)(C)C UWCBNAVPISMFJZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000000890 drug combination Substances 0.000 abstract 1
- 229960002711 epanolol Drugs 0.000 abstract 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 1
- MPGBPFMOOXKQRX-UHFFFAOYSA-N indenolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CC2 MPGBPFMOOXKQRX-UHFFFAOYSA-N 0.000 abstract 1
- 229950008838 indenolol Drugs 0.000 abstract 1
- 229960001632 labetalol Drugs 0.000 abstract 1
- 229960000831 levobunolol Drugs 0.000 abstract 1
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 abstract 1
- 229960004844 lovastatin Drugs 0.000 abstract 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 abstract 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 abstract 1
- 229960003134 mepindolol Drugs 0.000 abstract 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 abstract 1
- 229960002704 metipranolol Drugs 0.000 abstract 1
- BLWNYSZZZWQCKO-UHFFFAOYSA-N metipranolol hydrochloride Chemical compound [Cl-].CC(C)[NH2+]CC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C BLWNYSZZZWQCKO-UHFFFAOYSA-N 0.000 abstract 1
- 229960002237 metoprolol Drugs 0.000 abstract 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 abstract 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 abstract 1
- 229950009116 mevastatin Drugs 0.000 abstract 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 abstract 1
- LFTFGCDECFPSQD-UHFFFAOYSA-N moprolol Chemical compound COC1=CC=CC=C1OCC(O)CNC(C)C LFTFGCDECFPSQD-UHFFFAOYSA-N 0.000 abstract 1
- 229950002481 moprolol Drugs 0.000 abstract 1
- 229960004255 nadolol Drugs 0.000 abstract 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 abstract 1
- UPZVYDSBLFNMLK-UHFFFAOYSA-N nadoxolol Chemical compound C1=CC=C2C(OCC(O)CC(/N)=N/O)=CC=CC2=C1 UPZVYDSBLFNMLK-UHFFFAOYSA-N 0.000 abstract 1
- 229960004501 nadoxolol Drugs 0.000 abstract 1
- 229950000754 nipradilol Drugs 0.000 abstract 1
- 229960004570 oxprenolol Drugs 0.000 abstract 1
- 229960002508 pindolol Drugs 0.000 abstract 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 abstract 1
- 229960002797 pitavastatin Drugs 0.000 abstract 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 abstract 1
- 229960001749 practolol Drugs 0.000 abstract 1
- DURULFYMVIFBIR-UHFFFAOYSA-N practolol Chemical compound CC(C)NCC(O)COC1=CC=C(NC(C)=O)C=C1 DURULFYMVIFBIR-UHFFFAOYSA-N 0.000 abstract 1
- 229960003712 propranolol Drugs 0.000 abstract 1
- 229960002370 sotalol Drugs 0.000 abstract 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 abstract 1
- 229960004605 timolol Drugs 0.000 abstract 1
- 229950000245 toliprolol Drugs 0.000 abstract 1
- RKUQLAPSGZJLGP-UHFFFAOYSA-N xibenolol Chemical compound CC1=CC=CC(OCC(O)CNC(C)(C)C)=C1C RKUQLAPSGZJLGP-UHFFFAOYSA-N 0.000 abstract 1
- 229950001124 xibenolol Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A találmány tárgya b-blokkoló szert és HMG-CoA reduktáz inhibitorttartalmazó gyógyszerkombináció, amely b-blokkoló szerként acebutololt,alprenololt, amosulalolt, arotinololt, atenololt, befunololt,betaxololt, bevantololt, bisoprololt, bopindololt, bukumololt,bufetololt, bufuralolt, bunitrololt, buprandololt, butofilololt,karazololt, karteololt, karvedilolt, celiprololt, cetamololt,klorandololt, dilevalolt, epanololt, indenololt, labetalolt,levobunololt, mepindololt, metipranololt, metoprololt, moprololt,nadololt, nadoxololt, nebivalolt, nipradilolt, oxprenololt,perbutololt, pindololt, praktololt, pronetalolt, propranololt,szotalolt, szufinalolt, talindolt, tertalololt, tiliszololt, timololt,toliprololt, xibenololt, vagy bármelyikük gyógyászatilag alkalmazhatósóját vagy szolvátját vagy a gyógyászatilag alkalmazható sószolvátját, míg HMG-CoA reduktáz inhibitorként cerivasztatint,itavasztatint, lovasztatint, mevasztatint, nikosztatint, nivasztatint,(E)-7-[4-(4-fluor-fenil)-6-izopropil-2-(metil-/metilszulfonil/-amino)-pirimidin-5-il]-(3R,5S)-3,5-dihidro-hept-6-én-karbonsavat, vagybármelyikük gyógyászatilag alkalmazható sóját vagy szolvátját vagy agyógyászatilag alkalmazható só szolvátját tartalmazza. Ó
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0001188A SE0001188D0 (sv) | 2000-04-03 | 2000-04-03 | New combination |
| SE0002352A SE0002352D0 (sv) | 2000-06-22 | 2000-06-22 | New combination |
| PCT/SE2001/000663 WO2001074394A1 (en) | 2000-04-03 | 2001-03-27 | New combination of a betablocker and a cholesterol-lowering agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0300332A2 true HUP0300332A2 (hu) | 2003-06-28 |
| HUP0300332A3 HUP0300332A3 (en) | 2005-03-29 |
Family
ID=26655059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0300332A HUP0300332A3 (en) | 2000-04-03 | 2001-03-27 | New combination of a betablocker and a cholesterol-lowering agent and pharmaceutical compositions containing them |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20030060477A1 (hu) |
| EP (1) | EP1272219B1 (hu) |
| JP (1) | JP2003528928A (hu) |
| KR (1) | KR20020086749A (hu) |
| CN (1) | CN1422161A (hu) |
| AR (1) | AR030414A1 (hu) |
| AT (1) | ATE347909T1 (hu) |
| AU (2) | AU4298501A (hu) |
| BR (1) | BR0109753A (hu) |
| CA (1) | CA2403160A1 (hu) |
| DE (1) | DE60125159T2 (hu) |
| EE (1) | EE200200570A (hu) |
| ES (1) | ES2276774T3 (hu) |
| HK (1) | HK1051325A1 (hu) |
| HU (1) | HUP0300332A3 (hu) |
| IL (1) | IL151589A0 (hu) |
| IS (1) | IS6554A (hu) |
| MX (1) | MXPA02009705A (hu) |
| MY (1) | MY136386A (hu) |
| NO (1) | NO20024732D0 (hu) |
| NZ (1) | NZ521351A (hu) |
| PL (1) | PL357813A1 (hu) |
| RU (1) | RU2002123591A (hu) |
| SK (1) | SK14102002A3 (hu) |
| WO (1) | WO2001074394A1 (hu) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| US7314640B2 (en) * | 2003-07-11 | 2008-01-01 | Mongkol Sriwongjanya | Formulation and process for drug loaded cores |
| GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
| ITMI20040145A1 (it) * | 2004-01-30 | 2004-04-30 | Acraf | L-moprololo lpiu' tartrato |
| US20060003001A1 (en) * | 2004-02-11 | 2006-01-05 | John Devane | Chronotherapeutic compositions and methods of their use |
| EP1771413B1 (en) * | 2004-05-03 | 2011-09-21 | Janssen Pharmaceutica NV | Benzofuran derivatives as selective androgen receptor modulators (sarms) |
| CN101022791B (zh) * | 2004-06-04 | 2011-11-16 | 麦兰实验室公司 | 含奈必洛尔的组合物 |
| BRPI0621942A2 (pt) | 2006-08-04 | 2011-10-18 | Aska Pharm Co Ltd | preparação que reduz uma concentração de um ácido graxo livre e/ou fibrinogênio no sangue, agente para redução da quantidade de um ácido graxo livre no sangue, agente para redução da quantidade de fibrinogênio no sangue, método de prevenção ou tratamento de hiper-acidemia de ácido graxo livre, sìndrome metabólica, diabetes tipo ii, complicações causadas por diabetes tipo ii, lipotoxicidade, metabolismo anormal de lipìdeos, intoleráncia à glicose, secreção prejudicada de insulina, gordura hepática, lipoproteinemia de hipo-alta densidade, ou trombose, e uso de uma preparação |
| GB0624282D0 (en) * | 2006-12-05 | 2007-01-10 | Cavalla David | Treatment of cachexia |
| KR20100045344A (ko) * | 2008-10-23 | 2010-05-03 | 한올바이오파마주식회사 | 방출성이 제어된 베타 아드레날린 차단제와 ＨＭＧ-ＣｏＡ 환원 효소 억제제의 신규 복합 조성물 |
| MX344885B (es) * | 2008-11-10 | 2017-01-10 | Psicofarma S A De C V | Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido. |
| CN102462844A (zh) * | 2010-11-05 | 2012-05-23 | 四川滇虹医药开发有限公司 | 一种替利洛尔的药物组合物及其制备方法 |
| WO2013157833A1 (ko) * | 2012-04-18 | 2013-10-24 | 서울대학교산학협력단 | 베타-차단제를 유효성분으로 포함하는 비만, 비만으로 인한 대사성 질환 및 골감소증 예방, 개선 또는 치료용 조성물 |
| CN103613586B (zh) * | 2013-11-01 | 2016-06-08 | 北京博爱旺康医药科技有限公司 | 一种旋光纯s-(-)-阿罗洛尔酸式盐及其制备方法和应用 |
| CN103626750B (zh) * | 2013-11-15 | 2016-02-24 | 北京博爱旺康医药科技有限公司 | 一种盐酸阿罗洛尔及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5175187A (en) * | 1989-03-06 | 1992-12-29 | Soorianarain Baligadoo | Synergistic compositions for the treatment of coronary insufficiency and methods of use thereof |
| US5455269A (en) * | 1989-03-06 | 1995-10-03 | Baligadoo; Soorianarain | Synergistic compositions of amiodarone and beta blockers |
| EP0677291A3 (en) * | 1991-03-18 | 1996-08-07 | Sepracor Inc | Composition and method containing optically pure S-metoprolol. |
| JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| NO177455C (no) * | 1993-06-04 | 1995-09-20 | Gerrit Elmenhorst | Anordning ved apparat for fremstilling av brannslukkende skum |
| CA2251972A1 (en) * | 1996-04-17 | 1997-10-23 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardiovascular disease |
| SE9602762D0 (sv) * | 1996-07-12 | 1996-07-12 | Astra Ab | Carton and blank for forming the same |
| US5998458A (en) * | 1997-06-25 | 1999-12-07 | University Technology Corporation | Method of treating heart failure |
| GT199800126A (es) * | 1997-08-29 | 2000-01-29 | Terapia de combinacion. | |
| EA200100704A1 (ru) * | 1998-12-23 | 2002-02-28 | Джи.Ди.Сирл Ллс | Комбинация для применения по сердечно-сосудистым показаниям |
-
2001
- 2001-03-21 AR ARP010101322A patent/AR030414A1/es unknown
- 2001-03-27 IL IL15158901A patent/IL151589A0/xx unknown
- 2001-03-27 RU RU2002123591/15A patent/RU2002123591A/ru not_active Application Discontinuation
- 2001-03-27 EE EEP200200570A patent/EE200200570A/xx unknown
- 2001-03-27 NZ NZ521351A patent/NZ521351A/en unknown
- 2001-03-27 JP JP2001572136A patent/JP2003528928A/ja active Pending
- 2001-03-27 SK SK1410-2002A patent/SK14102002A3/sk not_active Application Discontinuation
- 2001-03-27 AU AU4298501A patent/AU4298501A/xx active Pending
- 2001-03-27 ES ES01916044T patent/ES2276774T3/es not_active Expired - Lifetime
- 2001-03-27 KR KR1020027013184A patent/KR20020086749A/ko not_active Application Discontinuation
- 2001-03-27 PL PL01357813A patent/PL357813A1/xx unknown
- 2001-03-27 AT AT01916044T patent/ATE347909T1/de not_active IP Right Cessation
- 2001-03-27 WO PCT/SE2001/000663 patent/WO2001074394A1/en not_active Application Discontinuation
- 2001-03-27 DE DE60125159T patent/DE60125159T2/de not_active Expired - Fee Related
- 2001-03-27 MX MXPA02009705A patent/MXPA02009705A/es unknown
- 2001-03-27 CA CA002403160A patent/CA2403160A1/en not_active Abandoned
- 2001-03-27 HU HU0300332A patent/HUP0300332A3/hu unknown
- 2001-03-27 CN CN01807652A patent/CN1422161A/zh active Pending
- 2001-03-27 BR BR0109753-9A patent/BR0109753A/pt not_active IP Right Cessation
- 2001-03-27 EP EP01916044A patent/EP1272219B1/en not_active Expired - Lifetime
- 2001-03-27 US US10/220,790 patent/US20030060477A1/en not_active Abandoned
- 2001-03-27 AU AU2001242985A patent/AU2001242985B2/en not_active Ceased
- 2001-04-02 MY MYPI20011564A patent/MY136386A/en unknown
-
2002
- 2002-09-19 IS IS6554A patent/IS6554A/is unknown
- 2002-10-02 NO NO20024732A patent/NO20024732D0/no unknown
-
2003
- 2003-05-23 HK HK03103659A patent/HK1051325A1/xx not_active IP Right Cessation
-
2004
- 2004-04-14 US US10/824,170 patent/US20040192784A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE60125159T2 (de) | 2007-10-25 |
| MXPA02009705A (es) | 2004-02-26 |
| WO2001074394A8 (en) | 2002-05-23 |
| EP1272219A1 (en) | 2003-01-08 |
| SK14102002A3 (sk) | 2003-06-03 |
| NO20024732L (no) | 2002-10-02 |
| IL151589A0 (en) | 2003-04-10 |
| US20040192784A1 (en) | 2004-09-30 |
| IS6554A (is) | 2002-09-19 |
| WO2001074394A1 (en) | 2001-10-11 |
| ATE347909T1 (de) | 2007-01-15 |
| US20030060477A1 (en) | 2003-03-27 |
| RU2002123591A (ru) | 2004-03-20 |
| NZ521351A (en) | 2004-08-27 |
| ES2276774T3 (es) | 2007-07-01 |
| EE200200570A (et) | 2004-04-15 |
| KR20020086749A (ko) | 2002-11-18 |
| PL357813A1 (en) | 2004-07-26 |
| NO20024732D0 (no) | 2002-10-02 |
| CN1422161A (zh) | 2003-06-04 |
| CA2403160A1 (en) | 2001-10-11 |
| AR030414A1 (es) | 2003-08-20 |
| AU2001242985B2 (en) | 2005-02-24 |
| HUP0300332A3 (en) | 2005-03-29 |
| DE60125159D1 (de) | 2007-01-25 |
| JP2003528928A (ja) | 2003-09-30 |
| BR0109753A (pt) | 2003-02-04 |
| AU4298501A (en) | 2001-10-15 |
| HK1051325A1 (en) | 2003-08-01 |
| MY136386A (en) | 2008-09-30 |
| EP1272219B1 (en) | 2006-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0300332A2 (hu) | Bétablokkoló és koleszterinszint-csökkentő szert tartalmazó új gyógyszerkombináció és ezt tartalmazó gyógyszerkészítmények | |
| JP2001523710A5 (hu) | ||
| NO20020968D0 (no) | Glukopyranosyloksypyrazolderivater, medisinske sammensetninger inneholdende det samme og intermediater forfremstillingen derav | |
| IL156167A (en) | Compounds of ABCA-1 for use in the preparation of a pharmacological preparation for the treatment of diseases following arterio-sclerosis | |
| CN1946384B (zh) | 治疗眼高压和青光眼的他汀类 | |
| DE69937691D1 (de) | Stabile arzneiformulierungen enthaltend pravastatin or atorvastatin | |
| ATE435013T1 (de) | Histon deazetylase enzym-hemmende hydroxamsäurederivate als neue entzündungshemmer zur hemmung der zytokinsynthese | |
| KR970705990A (ko) | 피부 질환 치료용 조성물(Compositions for the Treatment of Skin Disorders) | |
| JP2004511435A5 (hu) | ||
| HK1047891A1 (en) | C-4 carbonate taxanes. | |
| NO20041060L (no) | Krystaller av hydroksynorefedrinderivat | |
| BR9609844A (pt) | Intermediários de daftila e dihidronaftila compostos composições e processos | |
| JP2002508320A5 (hu) | ||
| CY1109546T1 (el) | Φαρμακο για την προληψη η θεραπεια της συχνουριας η της ουρικης ακρατειας | |
| PT1150667E (pt) | Alcool de cadeia longa de ciclo-hexenona para tratamento de esclerose amiotrofica lateral | |
| EP1488808A4 (en) | MEANS FOR THE TREATMENT OF GLOMERULAR DISEASES | |
| EP1275388A4 (en) | TNF ALPHA INHIBITORS | |
| BR9810616A (pt) | Inibidores de farnesil transferase em combinação com inibidores de hmg coa redutase para o tratamento do cancer | |
| ATE333897T1 (de) | Arzneimittel mit chymaseinhibitoren als wirksames mittel zur behandlung von dermatitis mit zweiphasigen hautreaktionen | |
| UY28729A1 (es) | Composiciones hipocolesterolemiantes | |
| GB2371748A (en) | HMG-COA reductase inhibitor extended release formulation | |
| RU2007148908A (ru) | Составы для снижения риска возникновения вызванной лекарственными средствами аритмии | |
| JPWO2004091660A1 (ja) | Ｌｋｌｆ／ｋｌｆ２遺伝子発現促進剤 | |
| SE0301846D0 (sv) | Use of certain compounds in treatment of obesity | |
| EP1296716B1 (en) | Use of a beta-blocker for the treatment of atherosclerosis |